REPLIMUNE GROUP, INC. Capital Expenditures
REPLIMUNE GROUP, INC. (REPL) reported Capital Expenditures of $449.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Cash Flow
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2023-08-03
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $449.00K, a 57.96% decline year-over-year.
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $251.00K, a 78.21% decline year-over-year.
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $555.00K, a 19.35% increase year-over-year.
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $396.00K, a 7.48% decline year-over-year.
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $2.27M, a 2.83% decline from fiscal 2022.
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $2.34M, a 2.34% decline from fiscal 2021.
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $2.39M, a 63.43% decline from fiscal 2020.
- REPLIMUNE GROUP, INC. payments to acquire property, plant, and equipment for fiscal 2020 was $6.54M, a 151.54% increase from fiscal 2019.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2023-06-30 | $449.00K 10-Q · filed 2023-08-03 | $700.00K derived: sum of 2 quarters · filed 2023-08-03 | $1.25M derived: sum of 3 quarters · filed 2023-08-03 | $1.65M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | $806.00K derived: sum of 2 quarters · filed 2023-05-18 | $1.20M derived: sum of 3 quarters · filed 2023-05-18 | $2.27M 10-K · filed 2023-05-18 |
| 2022-12-31 | $555.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09 | $951.00K derived: sum of 2 quarters · filed 2023-02-09 | $2.02M 10-Q · filed 2023-02-09 | $3.17M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-09-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03 | $1.46M 10-Q · filed 2022-11-03 | $2.62M derived: sum of 3 quarters · filed 2023-08-03 | $3.08M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-06-30 | $1.07M 10-Q · filed 2023-08-03 | $2.22M derived: sum of 2 quarters · filed 2023-08-03 | $2.69M derived: sum of 3 quarters · filed 2023-08-03 | $3.11M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | $1.62M derived: sum of 2 quarters · filed 2023-05-18 | $2.04M derived: sum of 3 quarters · filed 2023-05-18 | $2.34M 10-K · filed 2023-05-18 |
| 2021-12-31 | $465.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09 | $893.00K derived: sum of 2 quarters · filed 2023-02-09 | $1.18M 10-Q · filed 2023-02-09 | $1.95M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $428.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03 | $719.00K 10-Q · filed 2022-11-03 | $1.49M derived: sum of 3 quarters · filed 2022-11-03 | $2.10M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $291.00K 10-Q · filed 2022-08-04 | $1.06M derived: sum of 2 quarters · filed 2022-08-04 | $1.68M derived: sum of 3 quarters · filed 2022-08-04 | $1.75M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | $1.39M derived: sum of 2 quarters · filed 2022-05-19 | $1.46M derived: sum of 3 quarters · filed 2022-05-19 | $2.39M 10-K · filed 2022-05-19 |
| 2020-12-31 | $615.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-03 | $690.00K derived: sum of 2 quarters · filed 2022-02-03 | $1.62M 10-Q · filed 2022-02-03 | $2.96M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-09-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-04 | $1.01M 10-Q · filed 2021-11-04 | $2.35M derived: sum of 3 quarters · filed 2021-11-04 | $6.40M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $932.00K 10-Q · filed 2021-08-06 | $2.27M derived: sum of 2 quarters · filed 2021-08-06 | $6.33M derived: sum of 3 quarters · filed 2021-08-06 | $7.11M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | $5.39M derived: sum of 2 quarters · filed 2021-05-20 | $6.18M derived: sum of 3 quarters · filed 2021-05-20 | $6.54M 10-K · filed 2021-05-20 |
| 2019-12-31 | $4.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-04 | $4.84M derived: sum of 2 quarters · filed 2021-02-04 | $5.20M 10-Q · filed 2021-02-04 | $7.05M derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | $784.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-05 | $1.15M 10-Q · filed 2020-11-05 | $2.99M derived: sum of 3 quarters · filed 2020-11-05 | $3.63M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $362.00K 10-Q · filed 2020-08-07 | $2.21M derived: sum of 2 quarters · filed 2020-08-07 | $2.84M derived: sum of 3 quarters · filed 2020-08-07 | $2.85M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $2.48M derived: sum of 2 quarters · filed 2020-06-03 | $2.48M derived: sum of 3 quarters · filed 2020-06-03 | $2.60M 10-K · filed 2020-06-03 |
| 2018-12-31 | $633.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13 | $636.00K derived: sum of 2 quarters · filed 2020-02-13 | $752.00K 10-Q · filed 2020-02-13 | $748.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-09-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-12 | $119.00K 10-Q · filed 2019-11-12 | $115.00K derived: sum of 3 quarters · filed 2020-06-03 | $121.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-06-30 | $116.00K 10-Q · filed 2019-08-14 | $112.00K derived: sum of 2 quarters · filed 2020-06-03 | $118.00K derived: sum of 3 quarters · filed 2020-06-03 | $219.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-03-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $2.00K derived: sum of 2 quarters · filed 2020-06-03 | $103.00K derived: sum of 3 quarters · filed 2020-06-03 | $136.00K 10-K · filed 2020-06-03 |
| 2017-12-31 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14 | $107.00K derived: sum of 2 quarters · filed 2019-02-14 | $140.00K 10-Q · filed 2019-02-14 | |
| 2017-09-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | $134.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $33.00K 10-Q · filed 2018-08-30 | |||
| 2017-03-31 | $238.00K 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |